ReviewCancer cell international2020
Reshaping the role of m6A modification in cancer transcriptome: a review.
Review in Cancer cell international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 51 citations in OpenAlex.
- TheGenes · 2026Article
- Messenger RNA therapy in bone and joint diseases: Rationale, delivery systems, and applications.Biomaterials translational · 2026Article
- Core transcriptional regulatory circuit-regulated IGF2BP3 stabilizes E2F2 mRNA via m6A modification in neuroblastoma.Carcinogenesis · 2025Article
- Targeting m6A methylation for early diagnosis and precision medicine in hepatocellular carcinoma.Cancer cell international · 2025Review
- Switching from messenger RNAs to noncoding RNAs,World journal of gastrointestinal oncology · 2025Review
- METTL4 and METTL5 as biomarkers for recurrence-free survival in hepatocellular carcinoma patients.Future oncology (London, England) · 2025Article
- Epitranscriptomic RNA mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- m6ATM: a deep learning framework for demystifying the m6A epitranscriptome with Nanopore long-read RNA-seq data.Briefings in bioinformatics · 2024Article
- Action of m6A-related gene signatures on the prognosis and immune microenvironment of colonic adenocarcinoma.Heliyon · 2024Article
- Role of NOncology reports · 2024Review
- RNA m6A methylation regulators in liver cancer.Cancer cell international · 2024Review
- The essential roles of mGenes & diseases · 2024Review
- The role of N6-methyladenosine modification in tumor angiogenesis.Frontiers in oncology · 2024Review
- Evidence for the potential role of m6A modification in regulating autophagy in models of amyotrophic lateral sclerosis.CytoJournal · 2024Article
- KIAA1429 facilitates progression of hepatocellular carcinoma by modulating m6A levels in HPN.Heliyon · 2023Article
- Direct m6A recognition by IMP1 underlays an alternative model of target selection for non-canonical methyl-readers.Nucleic acids research · 2023Article
- CSNK1D-mediated phosphorylation of HNRNPA2B1 induces miR-25-3p/miR-93-5p maturation to promote prostate cancer cell proliferation and migration through mCellular and molecular life sciences : CMLS · 2023Article
- METTL3-Mediated LncRNAInternational journal of molecular sciences · 2023Article
- RNA m6A methylation regulators in endometrial cancer (Review).International journal of oncology · 2022Article
- Gene signatures, immune infiltration, and drug sensitivity based on a comprehensive analysis of m6a RNA methylation regulators in cervical cancer.Journal of translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N6-methyl-adenosine(m6A) modification emerges as an abundant and dynamic regulation throughout the Eukaryotic transcriptome. Dysregulation of the m6A regulators has increasingly been found in many neoplasms. It is reasonable to believe that m6A changes the fate of cancer cells and subsequently affected all aspects of cancer progression. In view of the context-dependent role of m6A modification, we emphasize a dual effect of m6A in a particular tumor model, that is, m6A plays a promoting role or a suppressing role in different stages of cancer. This novel sight is compared to the older view that a particular m6A regulator acts as a consistent role in cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.